Oral AC-1202 was designed to elevate serum ketone levels safely and efficiently, regardless of carbohydrate status of the diet. We have shown that AC-1202 improves memory and cognition in patients with mild-to-moderate AD  and in AAMI.
The effects of AC-1202 were more marked in the ApoE4-negative subpopulation, supporting previous findings that there are metabolic differences between E4-positive and E4-negative AD. This suggests that AD patients with varying ApoE genotypes may have different dose-response patterns, or that the differences between ApoE genotypes reflect differences in pathophysiology or stage of disease. A
SarahAnne wrote: By about the 4th to 7th day, I become very sluggish.
So, if I am understanding all of this, E4 carriers, who are seeking the potentially neuroprotective properties of ketosis, could use MCTs and avoid hyperlipidemia. Intriguing
Users browsing this forum: No registered users and 6 guests